Key facts
- This page summarizes Gail Cawkwell's Form 4 filing for INTERCEPT PHARMACEUTICALS, INC..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 31 Jan 2022, 15:14.
Gail Cawkwell - 27 Jan 2022 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC.
- Reporting relationship
- SVP, Med Affairs, Safety & PV
- Issuer ticker
- N/A
- Reported as of
- 27 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2022, 15:14:12 UTC
- Prior SEC filing
- 04 Jan 2022
- Next SEC filing
- 15 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rocco Venezia, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gail Cawkwell filed Form 4 for INTERCEPT PHARMACEUTICALS, INC. on 31 Jan 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ICPT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,600
- Change %
- +22%
- Price
- $0.000000
- Shares after
- 36,060
- Date
- 27 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ICPT
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +11,300
- Change %
- Price
- $0.000000
- Shares after
- 11,300
- Date
- 27 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,300
- Exercise price
- $14.44
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022.
Footnote F2
The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022.